Juq-470 !new! -

JUQ-470 — Field Dossier, History, and Narrative

2.2 Recursive Selective Decay

The defining feature of JUQ-470 is Recursive Selective Decay (RSD). In a standard neural net, "garbage collection" deletes unused data. In JUQ-470, RSD actively degrades high-fidelity data into low-fidelity abstractions.

When a system running JUQ-470 encounters a high-frequency event, it does not strengthen the memory trace; it weakens the granularity of the trace to prevent overfitting. Conversely, anomalies (low-frequency, high-impact events) are assigned rigid, high-fidelity λ values. This creates a cognitive landscape where the mundane fades into the subconscious background, allowing the anomalous to remain in sharp relief. JUQ-470

6. Early Clinical Development (if any)

• Phase I (First‑in‑Human) – Planned / Ongoing (as of early 2024): JUQ-470 — Field Dossier, History, and Narrative 2

  • Design: Open‑label, dose‑escalation (3 + 3 design), oral daily dosing.
  • Population: Adults with advanced solid tumors refractory to standard therapy, enriched for FGFR1/2/3 alterations or high VEGF expression.
  • Primary endpoints: Safety/tolerability, MTD (Maximum Tolerated Dose), PK (pharmacokinetics).
  • Secondary endpoints: Preliminary antitumor activity (RECIST v1.1), pharmacodynamic biomarkers (phospho‑FGFR1 in tumor biopsies, circulating VEGF levels).

• Key interim findings (presented at ESMO 2024): Phase I (First‑in‑Human) – Planned / Ongoing (as

  • MTD identified at 80 mg QD (once‑daily).
  • Common AEs (≥20 %): mild fatigue, nausea, transient hypertension (grade 1–2), hyperphosphatemia.
  • Pharmacokinetics: Median Tmax ≈ 4 h, half‑life ≈ 12 h, supporting QD dosing.
  • Efficacy signal: 2 partial responses (PR) in FGFR1‑amplified cholangiocarcinoma and FGFR2‑rearranged intra‑hepatic cholangiocarcinoma; disease stabilization ≥6 months in 5 patients.

Note: These clinical data are preliminary and have not yet been peer‑reviewed. The trial is still recruiting in several sites across North America and Europe.

Classification

• Designation: JUQ-470
• Type: Autonomous reconnaissance platform (terrestrial/aerial hybrid)
• Origin: Experimental program, Solstice Dynamics Division (fictional)
• Status: Deployed (limited field trials); active protocols archived under codename “Pleiades”

Speculative Future Variants

• JUQ-470B: Extended-endurance variant with hydrogen fuel cell and larger payload bay for extended chemical/biological sampling arrays.
• JUQ-470S: Silent-run version with optimized blade design and reduced thermal output for urban stealth.
• JUQ-470M: Modular mission rack allowing for electronic warfare payloads, non-lethal area denial, or extended comms relay.